ENO2 and non-small cell lung carcinoma: Significantly, shorter survival rates have been associated with high levels of circulating tumor biomarkers, e.g., cytokeratin-19 fragment, neuron-specific enolase (NSE), and thymidine kinase, in patients with non-small-cell lung carcinoma (NSCLC) [10].